Document Detail


The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey.
MedLine Citation:
PMID:  20541309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The course of hereditary angioedema (HAE) and the efficacy and safety of human C1-INH concentrate were appraised during pregnancy and the postpartum period, in patients with HAE.
STUDY DESIGN: Retrospective analysis of clinical data on 118 pregnancies (82 full-term and 36 abortions) in 41 female patients, extracted from the National HAE Registry, medical charts and patient diaries.
RESULTS: HAE attack frequency increases in 48% of pregnancies, whereas 33% of pregnancies were associated with mitigation of clinical signs and 19% of the pregnancies had no influence on the course of HAE, as compared to disease severity seen during the 2-year period preceding the pregnancy. During 46 full-term pregnancies, 26 patients reported attacks; 52% of these occurred in the third trimester. Abdominal attacks are the most common presentation of HAE during pregnancy. Attack number was significantly higher in patients who had sustained their initial attack before 8 years of age. Attack number increased during the third trimester if the fetus was afflicted by HAE. During the postpartum period, attacks occurred in 6/82 pregnancies. Patients received 91 vials of C1-INH concentrate altogether for the relief of acute attacks and for short- or long-term prophylaxis during pregnancy. This therapy was effective in all instances; no adverse effects were observed.
CONCLUSIONS: Pregnancy can either aggravate or mitigate edematous attacks, or alternatively, it may have no influence on the severity of the disease. According to our experience, C1-INH concentrate is an effective and safe therapeutic option during pregnancy.
Authors:
Ibolya Czaller; Beáta Visy; Dorottya Csuka; George Füst; Ferenc Tóth; Henriette Farkas
Related Documents :
19428119 - Pregnancy outcomes among women with panic disorder - do panic attacks during pregnancy ...
22693309 - Spontaneous pneumomediastinum.
19211489 - The risk of aneurysmal subarachnoid hemorrhage during pregnancy, delivery, and the puer...
10976199 - Cytodifferentiation during spermiogenesis in lumbricus terrestris.
16487879 - Metabolic diseases and pregnancy.
1373449 - The effects of glycol methacrylate as a dehydrating agent on the dimensional changes of...
10796119 - Energy/protein restriction for high weight-for-height or weight gain during pregnancy.
12825969 - Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions...
18768019 - Evaluation of two soft manual toothbrushes with different filament designs in relation ...
Publication Detail:
Type:  Journal Article     Date:  2010-06-11
Journal Detail:
Title:  European journal of obstetrics, gynecology, and reproductive biology     Volume:  152     ISSN:  1872-7654     ISO Abbreviation:  Eur. J. Obstet. Gynecol. Reprod. Biol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-23     Completed Date:  2010-12-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375672     Medline TA:  Eur J Obstet Gynecol Reprod Biol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  44-9     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortion, Induced / statistics & numerical data
Abortion, Spontaneous / epidemiology
Adolescent
Adult
Angioedemas, Hereditary / drug therapy*
Antifibrinolytic Agents / therapeutic use
Complement C1 Inhibitor Protein / therapeutic use*
Danazol / therapeutic use
Delivery, Obstetric
Female
Humans
Hungary / epidemiology
Infant, Newborn
Male
Pregnancy
Pregnancy Complications / drug therapy
Retrospective Studies
Young Adult
Chemical
Reg. No./Substance:
0/Antifibrinolytic Agents; 0/Complement C1 Inhibitor Protein; 17230-88-5/Danazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  "You feel like you can't live anymore": Suicide from the perspectives of Canadian men who experience...
Next Document:  Environmental management framework for wind farm siting: methodology and case study.